Business Standard

Sunday, December 22, 2024 | 12:41 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Sun Pharma to launch its first innovative product for psoriasis in Japan

Nod for Ilumya, a specialty product, would strengthen firm's dermatology portfolio in Japan, but analysts caution that the segment has been witnessing price erosion of late

Sun Pharma
Premium

Sun Pharma's stock reacted positively to the news, ending the day at Rs 481.8 on BSE, up marginally

Sohini Das Mumbai
Sun Pharmaceutical Industries got approval for its psoriasis drug Ilumya, a part of its specialty products portfolio, for the Japan market. This would strengthen Sun Pharma's dermatology portfolio in Japan, but analysts caution that the segment has been witnessing price erosion of late. 

It is the first innovative drug that Sun would launch in Japan. The approval was expected earlier by analysts. 

Sun Pharma's stock reacted positively to the news, ending the day at Rs 481.8 on BSE, up marginally.

On Monday the company said that one of its wholly-owned subsidiaries got approval from  Ministry of Health, Labour and Welfare (MHLW), Japan for

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in